Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01482663
Other study ID # CHE-2011-Geh
Secondary ID
Status Completed
Phase N/A
First received November 23, 2011
Last updated December 2, 2014
Start date May 2011
Est. completion date December 2012

Study information

Verified date December 2014
Source University Hospital, Gentofte, Copenhagen
Contact n/a
Is FDA regulated No
Health authority Denmark: The Regional Committee on Biomedical Research EthicsDenmark: Danish Dataprotection Agency
Study type Interventional

Clinical Trial Summary

Hand eczema is a common disease which often gives a chronic course thus affecting many functions in daily life. The body of evidence related to self-management of chronic hand eczema is poor. Better methods to support self-management of patients with chronic hand eczema may potentially improve the prognosis of a disease which is both a tremendous burden to the individual and to the society. The purpose of this trial is to evaluate the effect of a newly designed guidance programme offering individual counselling compared to conventional information with written information sheets.


Description:

Detailed description of the trial and the intervention can be found in the publication:

Mollerup A, Veien NK, Johansen JD. Chronic hand eczema--self-management and prognosis: a study protocol for a randomised clinical trial'. BMC Dermatol. 2012 Jun 12;12:6. doi: 10.1186/1471-5945-12-6.

PMID: 22691871 [PubMed - indexed for MEDLINE] Free PMC Article


Recruitment information / eligibility

Status Completed
Enrollment 306
Est. completion date December 2012
Est. primary completion date November 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Patients clinically diagnosed with hand eczema at the first medical consultation at the outpatient ward, Copenhagen University Hospital Gentofte or at a private dermatologic practise in Aalborg, Denmark

- Patients who have given a signed informed consent to participate

Exclusion Criteria:

- Patients who cannot reply to a questionnaire in Danish

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Intervention

Behavioral:
Healthy Skin Clinic
The intervention is founded upon three concurrent elements. Firstly, a SKIN-profile generated by data from a baseline questionnaire (S=Susceptibility, K=Competencies, I=Individual characteristics, N=Necessary precautions). Secondly, a patient self-management book which includes a patient's log and is offered in both an online and a physical form. Also support to self-management is offered through possible asynchronous communication and networking. Finally, a counselling consultation with a nurse, trained within dermatology.

Locations

Country Name City State
Denmark Dermatologic practise, Vesterbro 99 Aalborg
Denmark Department of Dermato-Allergology, Copenhagen University Hospital Gentofte Hellerup

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Gentofte, Copenhagen TrygFonden, Denmark

Country where clinical trial is conducted

Denmark, 

References & Publications (2)

Mollerup A, Veien NK, Johansen JD. An analysis of gender differences in patients with hand eczema - everyday exposures, severity, and consequences. Contact Dermatitis. 2014 Jul;71(1):21-30. doi: 10.1111/cod.12206. Epub 2014 Mar 12. — View Citation

Mollerup A, Veien NK, Johansen JD. Effectiveness of the Healthy Skin Clinic--a randomized clinical trial of nurse-led patient counselling in hand eczema. Contact Dermatitis. 2014 Oct;71(4):202-14. doi: 10.1111/cod.12243. Epub 2014 Apr 25. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Hand Eczema Severity Index (HECSI) Objective assessment of disease severity, measured by HECSI-score at time = 6 months versus HECSI-score at time = 0. 6 months No
Secondary Dermatology Life Quality Index (DLQI) DLQI measured by questionnaire at time = 6 months versus DLQI measured by questionnaire at time = 0. 6 months No
Secondary Overall burden of disease (VAS) VAS measured by questionnaire at time = 6 months versus VAS measured by questionnaire at time = 0. 6 months No
Secondary Danish version of The Medication Adherence Report Scale (DMARS-4) DMARS-4 measured by questionnaire at time = 6 months versus DMARS-4 measured by questionnaire at time = 0 months. 6 months No
See also
  Status Clinical Trial Phase
Withdrawn NCT05545215 - Prospective Real-World Clinical Investigation on Dexyane Med® in Adults With Chronic Hand Eczema
Completed NCT05486117 - Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema Phase 1
Recruiting NCT06004050 - A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema Phase 3
Recruiting NCT05682859 - Treatment of Chronic Hand Eczema With Oral Roflumilast (HERO) Phase 4
Recruiting NCT05994976 - Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
Completed NCT03683719 - Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema Phase 2
Completed NCT04872101 - Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2) Phase 3
Completed NCT04871711 - Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema Phase 3
Recruiting NCT05026554 - Characterization of Chronic Hand Eczema
Completed NCT05259722 - A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema Phase 3
Recruiting NCT03861455 - Efficacy and Safety of Dupilumab Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids Phase 2
Recruiting NCT05355818 - Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema Phase 3
Completed NCT04949841 - Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials Phase 3
Completed NCT03246776 - Microbial Colonization and Change of Chronic Keratinized Hand Eczema After Using Halometasone Triclosan Phase 4
Not yet recruiting NCT06283550 - Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy Phase 2
Completed NCT04378569 - Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema Phase 1/Phase 2